High Risk Proliferative Diabetic Retinopathy
3
0
0
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Panretinal Photocoagulation Prp
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (3)
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
Research Network
Common Treatments
- Panretinal Photocoagulation Prp3
- Intravitreous Injection Of Ranibizumab2
- Pegaptanib1
Active Sponsors
- Association for Innovation and Biomedical Research on Light and Image2
- José Cunha-Vaz1
- European Vision Institute Clinical Research Network1
Top Investigators
Association of Innovation and Biomedical Research on Light and Image
Center for Clinical Trials - Association for Innovation and Biomedical Research on Light and Image
Association for Innovation and Biomedical Research on Light and Image
Related Conditions
- Diabetes Mellitus Type Ii1
- Diabetes Mellitus Type I1